Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats

Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats

Author Nakamura-Palacios, E. M. Google Scholar
Bueno, OFA Google Scholar
Takahashi, R. N. Google Scholar
Tufik, S. Google Scholar
Institution Fed Univ Espirito Santo
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal de Santa Catarina (UFSC)
Abstract Yawning is a reflex or event that is not fully understood. It is controlled by many neurotransmitters and neuropeptides and can be induced pharmacologically by cholinergic or dopaminergic agonists. Amongst their many actions, cannabinoids acting on cannabinoid (CB1 or CB2) receptors can alter cholinergic and/or dopaminergic activity. This study examined the effects of Delta(8)-tetrahydrocannabinol (Delta(8)-THC) administered acutely (2.5 mg/kg intraperitoneally [ip], 15 min before test) or chronically (5 mg/kg for 30 days followed by 24 h or 7 days of discontinuation) on yawning induced by pilocarpine, a cholinergic agonist (0, 1, 2, 4 or 8 mg/kg ip), or apomorphine, a dopaminergic agonist (0, 20, 40 or 80 mug/kg subcutaneously [sc]). Acute effects of different doses of Delta(9)-tetrahydrocannabinol (Delta(9)-THC: 0, 0.5,.1.25 or 2.5 mg/kg ip) on yawning induced by pilocarpine (2 mg/kg ip) or apomorphine (40 mug/kg sc) were also investigated. Both pilocarpine and apomorphine produced yawning in a dose-related manner. Acute administration of Delta(8)-THC and Delta(9)-THC significantly reduced yawning induced by both pilocarpine and apomorphine. Chronic administration of Delta(8)-THC did not change yawning induced by either agonist 24 h or 7 days after discontinuation of Delta(8)-THC. However, a high frequency of spontaneous yawning was observed 7 days after Delta(8)-THC discontinuation. These results suggest that cannabinoid agonists inhibited yawning induced by cholinergic or dopaminergic agonists. in addition, the increased frequency of spontaneous yawning following cessation of chronic administration of a cannabinoid agonist may be of importance as a withdrawal sign for these drugs. (C) 2002 Elsevier Science Inc. All rights reserved.
Keywords cannabinoids
Language English
Date 2002-12-01
Published in Pharmacology Biochemistry and Behavior. Oxford: Pergamon-Elsevier B.V., v. 74, n. 1, p. 205-212, 2002.
ISSN 0091-3057 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 205-212
Access rights Closed access
Type Article
Web of Science ID WOS:000178798300023

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account